Cyclerion Therapeutics Inc Stock Price, News & Analysis

Cyclerion Therapeutics (NASDAQ: CYCN) has announced participation in two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13-15, 2021, featuring an on-demand session starting September 13 at 7:00 a.m. EDT. Additionally, the Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for September 30, 2021, at 2:40 p.m. EDT. Live webcasts can be accessed through the Investors & Media section of Cyclerion's website, with archived versions available for 90 days.

Cyclerion Therapeutics announces participation in the Annual Biomarkers for Alzheimer's Disease Summit on August 25-26, 2021. Presenters include Chris Winrow, Ph.D., discussing early clinical assessment of biomarkers for Alzheimer’s therapies, and Juli Jones, Ph.D., focused on omics platforms in drug discovery. Key presentations occur on August 25 at 4:20 p.m. ET and August 26 at 2:30 p.m. ET, followed by a Q&A. Cyclerion is advancing CY6463, targeting cognitive function restoration in diseases like Alzheimer's and schizophrenia.

Cyclerion Therapeutics reported significant advancements in clinical development for CY6463, a CNS-penetrant sGC stimulator, targeting Alzheimer's disease with vascular pathology (ADv) and related conditions. The FDA approved the IND application for CY6463, initiating a 12-week Phase 2a trial in ADv. Cyclerion raised approximately $30.5 million through private placements and an ATM offering in Q2 2021. The net loss decreased to $16.2 million from $19.5 million year-over-year. The company is also progressing CY3018 and has partnerships aimed at enhancing clinical developments.

Cyclerion Therapeutics (Nasdaq: CYCN) is set to present its Phase 2a study design for its lead candidate, CY6463, targeting Alzheimer’s disease with vascular pathology at the Alzheimer’s Association International Conference 2021, occurring from July 26-30, 2021. The research showcases neuropsychological biomarkers as predictors of cognitive performance in Alzheimer's patients. Cyclerion's innovative approach aims to restore cognitive function, as the company continues to advance treatments for various CNS disorders, with CY6463 demonstrating promise in earlier studies.

Cyclerion Therapeutics (Nasdaq: CYCN) and Beacon Biosignals have expanded their strategic partnership to enhance the development of Cyclerion's therapeutics targeting neurological diseases linked to cognitive impairment. Utilizing Beacon's EEG neurobiomarker platform, the collaboration aims to identify biomarkers for better patient selection and clinical endpoints. Cyclerion’s lead candidate, CY6463, has shown promising impacts on EEG parameters and is being evaluated in various ongoing studies, including those for Alzheimer's disease and schizophrenia.

Cyclerion Therapeutics (Nasdaq: CYCN) has announced an expanded strategic partnership with Beacon Biosignals to enhance data collection and analytics for developing investigational therapeutics targeting neurological diseases linked to cognitive impairment. This collaboration aims to identify relevant biomarkers and improve patient selection for Cyclerion's clinical studies, including those for CY6463, a CNS-penetrant sGC stimulator. Ongoing studies focus on conditions like Alzheimer’s with vascular pathology and cognitive impairment associated with schizophrenia.

Cyclerion Therapeutics has entered a global licensing agreement with Akebia Therapeutics for the development of praliciguat, a treatment for kidney disease. Cyclerion is set to receive up to $585 million in potential milestone payments and tiered royalties. This deal allows Cyclerion to concentrate on its key projects, CY6463 and CY3018, which target cognitive impairment. The agreement positions Cyclerion to benefit from Akebia's expertise in kidney disease, enhancing its strategic focus on developing CNS therapies.

Cyclerion Therapeutics announced a private sale of approximately $18 million in common stock to several notable investors, aimed at funding the clinical development of CY6463 and advancing the CY3018 program. The private placement involves selling 5,735,988 shares at $3.12 per share.

CEO Peter Hecht emphasized the capital will accelerate studies for CY6463, targeting cognitive impairment linked to various neurological diseases. The company plans to register the securities with the SEC within 10 business days.

Cyclerion Therapeutics (CYCN) announced the publication of preclinical data on CY6463, a first-in-class, CNS-penetrant sGC stimulator aimed at treating neurological diseases tied to cognitive impairment, including Alzheimer's disease with vascular pathology. The studies demonstrated that CY6463 improves neuronal function and cognitive performance while showing favorable safety and tolerability in initial clinical studies. Cyclerion is advancing a Phase 2 study of CY6463 in MELAS patients and plans further studies in Alzheimer's and Schizophrenia-related cognitive impairment.